keyword
MENU ▼
Read by QxMD icon Read
search

Insuline Glargin

keyword
https://www.readbyqxmd.com/read/29202547/predictors-of-glycemic-response-and-change-in-hba1c-following-newly-initiated-basal-insulin-among-insulin-na%C3%A3-ve-adults-with-type-2-diabetes
#1
Mojtaba Malek, Rokhsareh Aghili, Ameneh Ebrahim Valojerdi, Mohammad Ebrahim Khamseh
This sub-analysis of the Iran-AFECT study was to determine the baseline characteristics are predicting the likelihood of attainment of HbA1c goal and changing in HbA1c after initiation of basal insulin glargine in insulin naïve people with type 2 diabetes not adequately controlled with oral glucose-lowering drugs. Iran-AFECT was a 24-week, prospective, multicenter, observational study of people with type 2 diabetes initiated or switched to insulin glargine. In this sub-analysis, we included all insulin naïve people...
September 2017: Acta Medica Iranica
https://www.readbyqxmd.com/read/29196025/pharmacological-variability-of-insulins-degludec-and-glargine-300u-ml-equivalent-or-not
#2
EDITORIAL
L Monnier, C Colette
No abstract text is available yet for this article.
November 14, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29181962/unmet-needs-in-children-with-diabetes-the-role-of-basal-insulin
#3
Stefano Tumini, Silvia Carinci
The goal of insulin therapy in people affected by type 1 diabetes mellitus consists in achieving an optimal metabolic control and so HbA1c levels below 7.5%, according to the conclusions of relevant scientific studies. In any case it seems that this target is far from being achieved, mostly in the pediatric population. However, many important pharmacological, technological and cultural milestones have been placed both in therapy and management of insulin-dependent diabetes even if the gap between growing knowledge in these fields and its application in daily clinical practice appears still too wide...
December 2017: Minerva Pediatrica
https://www.readbyqxmd.com/read/29179974/glycaemic-responses-in-asian-and-non-asian-people-with-type-2-diabetes-initiating-insulin-glargine-100-units-ml-a-patient-level-pooled-analysis-of-16-randomised-controlled-trials
#4
Juliana C N Chan, Pongamorn Bunnag, Siew P Chan, Iris T I Tan, Shih-Tzer Tsai, Ling Gao, Wolfgang Landgraf
AIMS: To compare outcomes between Asian and non-Asian patients with type 2 diabetes (T2D) inadequately controlled on oral antidiabetic drugs (OADs) initiating insulin glargine 100 units/mL (Gla-100) in randomised controlled clinical trials. METHODS: Post hoc analysis of patient-level data (Asian n = 235; non-Asian n = 3,351) from 16 trials. RESULTS: At baseline, Asian patients were younger with lower body mass index (BMI), fasting C-peptide and fasting plasma glucose (FPG) than non-Asian patients (all P < 0...
November 24, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29179857/transition-from-intravenous-insulin-to-subcutaneous-long-acting-insulin-in-critical-care-patients-on-enteral-or-parenteral-nutrition
#5
Analía Ramos, Lluis Zapata, Paula Vera, Antoni J Betbese, Antonio Pérez
BACKGROUND AND AIMS: The optimal initial dose of subcutaneous (SC) insulin after intravenous (IV) infusion is controversial, especially in patients receiving continuous enteral nutrition (EN) or total parenteral nutrition (TPN). The aim of this study was to evaluate the strategy used at our hospital intensive care unit (ICU) in patients switched from IV insulin to SC insulin glargine while receiving EN or TPN. DESIGN AND METHODS: A retrospective analysis was made of 27 patients on EN and 14 on TPN switched from IV infusion insulin to SC insulin...
December 2017: Endocrinología, Diabetes y Nutrición
https://www.readbyqxmd.com/read/29167192/cytokeratin-18-and-enhanced-liver-fibrosis-scores-in-type-1-and-type-2-diabetes-and-effects-of-two-different-insulins
#6
Arun Sanyal, Kenneth Cusi, Mark L Hartman, Shuyu Zhang, Edward J Bastyr, Juliana M Bue-Valleskey, Annette M Chang, Axel Haupt, Scott J Jacober, Robert J Konrad, Qianyi Zhang, Byron J Hoogwerf
Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited. This study analyzed phase III data comparing basal insulin peglispro (BIL) and insulin glargine in type 1 (T1D), and type 2 diabetes (T2D) (insulin-naïve and insulin-treated). Alanine aminotransferase (ALT), K-18, ELF scores and liver fat content (LFC), measured by MRI, were obtained longitudinally. Baseline K-18 (U/L) was higher in T2D (range: 207‒247) than T1D (range: 148‒183), correlated with ALT in all populations (r (range) 0...
November 21, 2017: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/29166786/understanding-concentrated-insulins-a-systematic-review-of-randomized-controlled-trials
#7
Fernando Ovalle, Alissa R Segal, John E Anderson, Michael R Cohen, Tina M Morwick, Jeffrey A Jackson
OBJECTIVE: To compile, analyze, and summarize the literature on concentrated insulins (i.e., concentrations >100 units/mL) from randomized controlled trials and derive guidance on appropriate use of these agents. METHODS: Searches were conducted in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and Trialtrove® (through April 2016) and ClinicalTrials.gov (through April 2017) for Phase 1-4 clinical studies using concentrated insulins. Selected studies included multiple-arm, randomized controlled trials evaluating subcutaneously administered concentrated insulins...
November 22, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29164973/an-indirect-treatment-comparison-of-the-efficacy-of-insulin-degludec-liraglutide-ideglira-and-insulin-glargine-lixisenatide-iglarlixi-in-patients-with-type-2-diabetes-uncontrolled-on-basal-insulin
#8
Marc Evans, Liana K Billings, Jonas Håkan-Bloch, Ulla Slothuus, Trine J Abrahamsen, Andreas Andersen, Jeroen P Jansen
AIMS: To obtain estimates of the relative treatment effects between insulin degludec/liraglutide (IDegLira) and insulin glargine U100/lixisenatide (iGlarLixi) in patients with type 2 diabetes mellitus (T2DM) uncontrolled on basal insulin therapy. MATERIALS AND METHODS: Data from phase 3 trials providing evidence for estimating the relative efficacy and safety of IDegLira versus iGlarLixi in patients uncontrolled on basal insulin-only regimens were used in this analysis...
November 22, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29160303/the-pnpla3-i148m-variant-is-associated-with-transaminase-elevations-in-type-2-diabetes-patients-treated-with-basal-insulin-peglispro
#9
S Pillai, S Duvvuru, P Bhatnagar, W Foster, M Farmen, S Shankar, C Harris, E Bastyr, B Hoogwerf, A Haupt
Basal insulin peglispro (BIL) is a novel insulin with hepato-preferential action. In phase 3 trials, BIL showed significantly improved glycemic control but higher levels of transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), triglycerides (TGs) and liver fat content (LFC) compared with insulin glargine (GL). As variants in PNPLA3 (I148M) and TM6SF2 (E167K) are associated with nonalcoholic fatty liver disease, we assessed these variants in type 2 diabetes (T2D) patients randomized to receive BIL (n=1822) or GL (n=1270) in three phase 3 trials...
November 21, 2017: Pharmacogenomics Journal
https://www.readbyqxmd.com/read/29160108/effects-of-hepato-preferential-basal-insulin-peglispro-on-nuclear-magnetic-resonance-biomarkers-lipoprotein-insulin-resistance-index-and-glyca-in-patients-with-diabetes
#10
Margery A Connelly, James D Otvos, Qianyi Zhang, Shuyu Zhang, Caryl J Antalis, Annette M Chang, Byron J Hoogwerf
AIM: To characterize the effects of hepato-preferential basal insulin peglispro (BIL) and insulin glargine on insulin resistance (lipoprotein insulin resistance index [LP-IR]) and inflammation (GlycA), and to explore the biological implications. METHODS: This substudy included 847 patients with Type 1 diabetes (T1D) or Type 2 diabetes (T2D) in four cohorts of the BIL development program. LP-IR and GlycA were measured before and after insulin treatment. Correlations between LP-IR, GlycA, clinical parameters and liver biomarkers were assessed...
November 2017: Biomarkers in Medicine
https://www.readbyqxmd.com/read/29155123/baseline-factors-associated-with-better-response-to-insulin-lispro-low-mixture-or-insulin-glargine-a-post-hoc-analysis-of-the-durable-study
#11
Nan Jia, Zbigniew Kindracki, Angel Rodriguez
AIMS: To identify baseline characteristics associated with better efficacy and safety responses to twice-daily insulin lispro low mixture (LM) or once-daily insulin glargine (IG) in insulin-naïve patients with type 2 diabetes (T2D). METHODS: This post hoc analysis of the DURABLE study used the gradient-boosting method to generate hypothetical outcomes with the alternative treatment to assigned study drug to evaluate the potential additional benefit of one insulin over the other in association with influential baseline covariates in the same patient...
November 16, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29153485/morning-administration-of-0-4u-kg-day-insulin-glargine-300u-ml-provides-less-fluctuating-24-hour-pharmacodynamics-and-more-even-pharmacokinetic-profiles-compared-with-insulin-degludec-100u-ml-in-type-1-diabetes
#12
T S Bailey, J Pettus, R Roussel, W Schmider, M Maroccia, N Nassr, O Klein, G B Bolli, R Dahmen
AIM: To compare steady state pharmacodynamic and pharmacokinetic profiles of insulin glargine 300U/mL (Gla-300) with insulin degludec 100U/mL (Deg-100) in people with type 1 diabetes. METHODS: This single-centre, randomized, double-blind crossover euglycaemic clamp study included two parallel cohorts with fixed once-daily morning dose regimens. For both insulins participants received 0.4 (n=24) or 0.6U/kg/day (n=24), before breakfast, for 8 days prior to the clamp...
November 16, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29143919/iglarlixi-reduces-glycated-hemoglobin-to-a-greater-extent-than-basal-insulin-regardless-of-levels-at-screening-post-hoc-analysis-of-lixilan-l
#13
Elisabeth Niemoeller, Elisabeth Souhami, Yujun Wu, Klaus H Jensen
INTRODUCTION: The treatment of patients with type 2 diabetes uncontrolled on basal insulin and oral glucose-lowering drugs was investigated previously in the LixiLan-L trial. In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks. In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA1c) levels from screening, both for the overall category and for screening HbA1c subcategories...
November 16, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29140602/the-cardiovascular-safety-of-long-acting-insulin-analogues-in-type-2-diabetes-is-there-a-better-basal-insulin
#14
Chia-Hsuin Chang, Lee-Ming Chuang
In 2008, the U.S. Food and Drug Administration requested that all new type 2 anti-diabetic drugs, including long-acting insulin analogues, need to be rigorously examined to preclude undesirable cardiovascular risks. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is the first trial to provide conclusive evidence of the cardiovascular safety of insulin glargine. A total of 12,537 people with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes were randomized to receive insulin glargine or standard care...
November 15, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29129018/a-32-week-randomized-comparison-of-stepwise-insulin-intensification-of-biphasic-insulin-aspart-biasp%C3%A2-30-versus-basal-bolus-therapy-in-insulin-na%C3%A3-ve-patients-with-type-2-diabetes
#15
Sultan Linjawi, Byung-Wan Lee, Ömür Tabak, Susanna Lövdahl, Shanti Werther, Salahedeen Abusnana
INTRODUCTION: This 32-week, open-label, randomized, parallel-group, multinational trial aimed to compare the efficacy and safety of stepwise insulin intensification of biphasic insulin aspart 30 (BIAsp 30) relative to stepwise intensification of a basal-bolus regimen in insulin-naïve adults with type 2 diabetes (T2D) who continued pretrial treatment with metformin and sulfonylurea. METHODS: Adults with T2D were randomized into one of two treatment arms for 32 weeks: (1) BIAsp 30 once daily (OD), with the possibility of stepwise treatment intensification up to BIAsp 30 three times daily (TID); (2) insulin glargine OD, with the possibility of stepwise treatment intensification with insulin aspart up to TID...
November 11, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29114384/treatment-with-insulin-analogs-and-prevalence-of-cardiovascular-complications-in-patients-with-type-1-diabetes
#16
Christoph Hasslacher, Justo Lorenzo Bermejo
Background: A lower incidence of cardiovascular events has been reported in type 2 diabetes patients treated with insulin analogs (IAs). Corresponding data on people affected by type 1 diabetes are not available yet. Methodology: We investigated demographic and clinical data from 509 type 1 diabetics, who were treated in an outpatient clinic from 2006 to 2012. Multiple logistic regression was used to investigate the relationship between the type of insulin treatment and the prevalence of cardiovascular (CV) complications, that is, presence of coronary heart, cerebrovascular and peripheral arterial diseases, adjusting for potential confounders...
November 2017: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29110972/patient-reported-outcomes-in-patients-with-type-2-diabetes-treated-with-dulaglutide-added-to-titrated-insulin-glargine-award-9
#17
Maria Yu, Kate Van Brunt, Zvonko Milicevic, Oralee Varnado, Kristina S Boye
PURPOSE: This 28-week, randomized, double-blind study compared a once-weekly injection of dulaglutide 1.5 mg to placebo, both added to titrated once-daily insulin glargine (with or without metformin), in patients with type 2 diabetes mellitus and inadequate glycemia control (control defined as hemoglobin A1c, ≥7% and ≤10.5%). Patient-reported outcomes were assessed as an exploratory objective to further understand patients' physical, psychological, and social aspects of well-being and injection-device experience...
November 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29106816/insulin-glargine-300-u-ml-is-associated-with-less-weight-gain-while-maintaining-glycemic-control-and-low-risk-of-hypoglycemia-compared-with-insulin-glargine-100-u-ml-in-an-aging-population-with-type-2-diabetes
#18
Medha N Munshi, Jasvinder Gill, Jason Chao, Elena V Nikonova, Meenakshi Patel
OBJECTIVE: Assess efficacy, hypoglycemia and weight gain in patients with type 2 diabetes (T2D) treated with insulin glargine 300 U/mL (Gla-300) or 100 U/mL (Gla-100) across different age groups. METHODS: Pooled data were generated for patients randomized to Gla-300 or Gla-100 in the EDITION 2 (NCT01499095) and 3 (NCT01676220) studies. In four age groups (<55, ≥55 to <60, ≥60 to <65, ≥65 years), glycated hemoglobin A1C (A1C), percentage of patients reaching A1C <7...
November 6, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29094298/optimizing-glycemic-control-through-titration-of-insulin-glargine-100-u-ml-a-review-of-current-and-future-approaches-with-a-focus-on-asian-populations
#19
REVIEW
Chaicharn Deerochanawong, Shailendra Bajpai, I Made Pande Dwipayana, Zanariah Hussein, Maria Aileen Mabunay, Reynaldo Rosales, Shih-Tzer Tsai, Man Wo Tsang
Various data have demonstrated inadequate glycemic control amongst Asians with type 2 diabetes mellitus (T2DM), possibly on account of suboptimal titration of basal insulin-an issue which needs to be further examined. Here we review the available global and Asia-specific data on titration of basal insulin, with a focus on the use of insulin glargine 100 U/mL (Gla-100). We also discuss clinical evidence on the efficacy and safety of titrating Gla-100, different approaches to titration, including some of the latest technological advancements, and guidance on the titration of basal insulin from international and local Asian guidelines...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29090977/observational-registry-of-basal-insulin-treatment-in-patients-with-type-2-diabetes-in-china-safety-and-hypoglycemia-predictors
#20
Tingting Zhang, Linong Ji, Yan Gao, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Fang Zhao, Heng Zhang, Xiaohui Guo
BACKGROUND: The Observational Registry of Basal Insulin Treatment (ORBIT) study evaluated the safety of basal insulin (BI) in real-world settings in China. METHODS: We analyzed 9002 patients with type 2 diabetes (T2D) inadequately controlled with oral hypoglycemic agents from 8 geographic regions and 2 hospital tiers in China who initiated and maintained BI treatment. Body weight and hypoglycemic episodes were recorded at baseline and 3 and 6 months. Serious adverse events (SAEs) were recorded at 3 and 6 months...
November 2017: Diabetes Technology & Therapeutics
keyword
keyword
49211
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"